Keyword: Senate Special Committee on Aging
The Senate Special Committee on Aging wants 5 pharmas to explain the rising cost of naloxone, a med that’s used to reverse the effects of opioids.
When Valeant CEO J. Michael Pearson and top shareholder Bill Ackman spoke at a Senate hearing on drug pricing, the gist was this: Valeant messed up. Big time.
It’s about that time: Valeant CEO J. Michael Pearson will take the hot seat today at a Senate hearing on the company’s drug pricing. And when he gets there, he plans to repent.
Valeant CEO Michael Pearson spent long hours under questioning in Washington, DC, on Monday as a Senate committee continued its probe of the company’s pricing policies.
After threats from Congress and a scolding from his own company, Valeant CEO Michael Pearson scheduled a deposition with a Senate committee investigating his company's price increases.